Drug Trial Radar · NCT00401375
Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)
Last checked: Nov 19, 2026Latest source record: Sep 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
524
Actual
Start
Oct 31, 2006
Primary completion
Feb 29, 2008
Study completion Feb 29, 2008
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Wyeth is now a wholly owned subsidiary of Pfizer
- First posted
- Nov 20, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of MNTX in participants who have undergone segmental colectomy and to assess if the time between the end of surgery and the first bowel movement is significantly shorter in the MNTX regimen than the equivalent assessment using a placebo regimen.
Conditions
- Post-Operative Ileus (POI)
Interventions
MethylnaltrexoneDrug
Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
PlaceboDrug
Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Bowel MovementTime frame: Day 1 (From the time of end of surgery [that is; from the first dose of study drug administration]) up to Day 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Progenics Pharmaceuticals
Tarrytown, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.